Stock ICO ICONOVO AB
Add to a list
To use this feature you must be a member
Log inSign up

News Iconovo AB

Equities

ICO

SE0010868943

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-09 pm EDT 		5-day change 1st Jan Change
8.7 SEK +0.23% Intraday chart for Iconovo AB -4.40% -24.68%
May. 15 Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments CI
May. 06 Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ICONOVO AB PUBLISHES THE ANNUAL REPORT 2023 IN ENGLISH
AQ
BioStock: Iconovo initiates development of inhaled obesity treatment
AQ
Iconovo files patent application for inhaled GLP-1 products and initiates development of new obesity treatments
AQ
Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments
CI
Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler
MT
Iconovo receives patent protection for ICOres® in China
AQ
Iconovo AB Receives Patent Protection for Icores in China
CI
Iconovo Q1 - Solid quarter with a near-term catalyst on the horizon
AQ
Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Iconovo to present positive data from a feasibility study on Nanofitins® in ICOone®
AQ
Iconovo AB and Affilogic to Present Positive Data from a Feasibility Study on Nanofitins in ICOone
CI
Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea
AQ
Iconovo Q4 - Aligned with our expectations and a directed issue announcement
AQ
Iconovo AB Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Iconovo AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Iconovo carries out a directed share issue of SEK 33.3 million, partly subject to subsequent approval by the Extraordinary General Meeting, and brings forward the publication of the year-end report
AQ
Iconovo signs additional contract with Kiox Pharma for the development of a new inhalable treatment for interstitial lung disease
AQ
Iconovo AB Signs Additional Contract with Kiox Pharma for the Development of A New Inhalable Treatment for Interstitial Lung Disease
CI
Iconovo launches improved versions of nasal ICOone® inhalers
AQ
Iconovo AB Launches Improved Versions of Nasal ICOone Inhalers
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ICO Stock
  4. News Iconovo AB